author-photo

Vahid Naini

Janssen Pharmaceutica

17

Papers

1046

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

851PDPatient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

2019 European Urology Supplements
Show All
- Source
- Cite
- Save
Citations (0)
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (31)
883PAndrogen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)
First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia

2017 Asian Journal of Urology
Show All
- Source
- Cite
- Save
Citations (11)
Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
556 Abiraterone acetate improves overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Impact of crossover and baseline prognostic factors in the COU-AA-302 final analysis

2015 European Urology Supplements
Show All
- Source
- Cite
- Save
Citations (0)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

2015 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (811)
Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (94)